0.0475 -0.022 (-31.16%) | 09-06 15:59 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.08 | 1-year : | 0.1 |
Resists | First : | 0.07 | Second : | 0.08 |
Pivot price | 0.04 | |||
Supports | First : | 0.04 | Second : | 0.01 |
MAs | MA(5) : | 0.04 | MA(20) : | 0.04 |
MA(100) : | 0.15 | MA(250) : | 0.95 | |
MACD | MACD : | 0 | Signal : | -0.1 |
%K %D | K(14,3) : | 50.4 | D(3) : | 50.4 |
RSI | RSI(14): 53.6 | |||
52-week | High : | 7.13 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRXT ] has closed below upper band by 43.3%. Bollinger Bands are 73% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 44 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.07 - 0.08 | 0.08 - 0.08 |
Low: | 0.05 - 0.05 | 0.05 - 0.05 |
Close: | 0.05 - 0.05 | 0.05 - 0.05 |
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Wed, 01 Mar 2023
CLARUS THERAPEUTICS HOLDINGS, INC. : Bankruptcy or Receivership, Completion of Acquisition or Disposition of ... - Marketscreener.com
Mon, 05 Sep 2022
Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process ... - GlobeNewswire
Mon, 29 Aug 2022
Clarus Therapeutics (CRXT) Stock Plunges Ahead of Aug. 31 Delisting - InvestorPlace
Tue, 10 May 2022
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + ... - GlobeNewswire
Thu, 28 Apr 2022
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate) - Yahoo Finance
Mon, 25 Apr 2022
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - General
|
|
Shares Out | 24 (M) |
Shares Float | 32 (M) |
Held by Insiders | 2.5 (%) |
Held by Institutions | 23.2 (%) |
Shares Short | 2,000 (K) |
Shares Short P.Month | 3,310 (K) |
EPS | -26.02 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -1.17 |
Profit Margin | -256.2 % |
Operating Margin | -271.8 % |
Return on Assets (ttm) | -89.6 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 72 % |
Gross Profit (p.s.) | 0.46 |
Sales Per Share | 0.65 |
EBITDA (p.s.) | -1.77 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -54 (M) |
Levered Free Cash Flow | -43 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | -0.05 |
Price to Sales | 0.07 |
Price to Cash Flow | -0.03 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |